Cart
sales@molnova.com
Giredestrant
CAS No. 1953133-47-5
Giredestrant( GDC-9545 )
Catalog No. M23885 CAS No. 1953133-47-5
Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 210 | In Stock |
|
| 5MG | 260 | In Stock |
|
| 10MG | 417 | In Stock |
|
| 25MG | 785 | In Stock |
|
| 50MG | 1251 | In Stock |
|
| 100MG | 1962 | In Stock |
|
| 200MG | 2673 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGiredestrant
-
NoteResearch use only, not for human use.
-
Brief DescriptionGiredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
-
DescriptionGiredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.
-
In Vitro——
-
In Vivo——
-
SynonymsGDC-9545
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorER
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1953133-47-5
-
Formula Weight522.55
-
Molecular FormulaC27H31F5N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100mg/mL (191.37 mM; Need ultrasonic)
-
SMILESC[C@H](Cc1c2[nH]c3c1cccc3)N(CC(CO)(F)F)[C@@H]2c(c(F)cc(NC1CN(CCCF)C1)c1)c1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
molnova catalog
related products
-
4',7-Dimethoxyisofla...
4', 7-dimethoxyisoflavone, a kind of isoflavonoids, showed inhibitory effects on rat prostate testosterone 5α-reductase.
-
Nafoxidine
Nafoxidine is an estrogen antagonist that has been used in the treatment of breast cancer.
-
Y134
Y134 is an estrogen receptor inhibitor that is selective and orally active, exhibiting strong antagonist activity against ERα and Erβ with Ki of 0.09 nM and 11.31 nM, respectively.
